Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA Jr, Hirsch FR, Varella-Garcia M. Cappuzzo F, et al. Among authors: ludovini v. Br J Cancer. 2005 Dec 12;93(12):1334-40. doi: 10.1038/sj.bjc.6602865. Br J Cancer. 2005. PMID: 16288303 Free PMC article.
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. Cappuzzo F, et al. Among authors: ludovini v. J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41. doi: 10.1093/jnci/djh217. J Natl Cancer Inst. 2004. PMID: 15292385 Clinical Trial.
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crinò L, Tonato M, Villa E. Gregorc V, et al. Among authors: ludovini v. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6006-12. doi: 10.1158/1078-0432.CCR-03-0770. Clin Cancer Res. 2004. PMID: 15447984
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Cappuzzo F, et al. Among authors: ludovini v. J Natl Cancer Inst. 2005 May 4;97(9):643-55. doi: 10.1093/jnci/dji112. J Natl Cancer Inst. 2005. PMID: 15870435 Clinical Trial.
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. Cappuzzo F, et al. Among authors: ludovini v. J Clin Oncol. 2005 Aug 1;23(22):5007-18. doi: 10.1200/JCO.2005.09.111. J Clin Oncol. 2005. PMID: 16051952
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Cusatis G, et al. Among authors: ludovini v. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42. doi: 10.1093/jnci/djj469. J Natl Cancer Inst. 2006. PMID: 17148776
Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Mihaylova Zh, Ludovini V, Gregorg V, Floriani I, Pistola L, Toffaneti F, Ferraldeschi M, Spreafico A, Ceresoli GL, Bellet M, Darwish S, Tonato M, Raynov J. Mihaylova Zh, et al. Among authors: ludovini v. J BUON. 2007 Jan-Mar;12(1):105-11. J BUON. 2007. PMID: 17436410 Clinical Trial.
93 results